Literature DB >> 1315761

Slow-binding inhibition of NAD+ glycohydrolase by arabino analogues of beta-NAD.

H M Muller-Steffner1, O Malver, L Hosie, N J Oppenheimer, F Schuber.   

Abstract

Modifications at the 2'-position of the nicotinamide-ribosyl moiety influence dramatically the nature of the interactions of the modified beta-NAD+ with calf spleen NAD+ glycohydrolase (EC 3.2.2.6), an enzyme that cleaves the nicotinamide-ribose bound in NAD(P)+. Nicotinamide arabinoside adenine dinucleotide (ara-NAD+) and nicotinamide 2'-deoxy-2'-fluoroarabinoside adenine dinucleotide (araF-NAD+) are not hydrolyzed at measurable rates and are the first documented examples of reversible slow binding inhibitors of this class of enzyme. The kinetic data obtained are consistent with both slow kon and koff rate constants in the formation of an enzyme-inhibitor complex, i.e. the association rate constants are about 10(4) and 10(6) slower than diffusion rates, respectively, for araF-NAD+ and ara-NAD+, and the half-life of the complex is about 3-10 min for both analogues. The kinetic model does not account for a slow turnover of an ADP-ribosyl-enzyme intermediary complex. AraF-NAD+ is one of the most potent inhibitors described for NAD+ glycohydrolase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315761

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Signaling properties of CD38 in the mouse immune system: enzyme-dependent and -independent roles in immunity.

Authors:  Frances E Lund
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

2.  Effects of NAD at purine receptors in isolated blood vessels.

Authors:  E Alefishat; S P H Alexander; V Ralevic
Journal:  Purinergic Signal       Date:  2014-10-15       Impact factor: 3.765

Review 3.  NAD glycohydrolases: a possible function in calcium homeostasis.

Authors:  H Kim; E L Jacobson; M K Jacobson
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

4.  Human CD38 is an authentic NAD(P)+ glycohydrolase.

Authors:  V Berthelier; J M Tixier; H Muller-Steffner; F Schuber; P Deterre
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

5.  Redesign of Schistosoma mansoni NAD+ catabolizing enzyme: active site H103W mutation restores ADP-ribosyl cyclase activity.

Authors:  Isabelle Kuhn; Esther Kellenberger; Didier Rognan; Frances E Lund; Hélène Muller-Steffner; Francis Schuber
Journal:  Biochemistry       Date:  2006-10-03       Impact factor: 3.162

6.  Design, synthesis and biological characterization of novel inhibitors of CD38.

Authors:  Min Dong; Yuan-Qi Si; Shuang-Yong Sun; Xiao-Ping Pu; Zhen-Jun Yang; Liang-Ren Zhang; Li-He Zhang; Fung Ping Leung; Connie Mo Ching Lam; Anna Ka Yee Kwong; Jianbo Yue; Yeyun Zhou; Irina A Kriksunov; Quan Hao; Hon Cheung Lee
Journal:  Org Biomol Chem       Date:  2011-03-23       Impact factor: 3.876

7.  Inhibition of the intrinsic NAD+ glycohydrolase activity of CD38 by carbocyclic NAD analogues.

Authors:  K A Wall; M Klis; J Kornet; D Coyle; J C Amé; M K Jacobson; J T Slama
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

Review 8.  NAD hydrolysis: chemical and enzymatic mechanisms.

Authors:  N J Oppenheimer
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

9.  Extracellular NAD+ regulates intracellular free calcium concentration in human monocytes.

Authors:  Anja Gerth; Karen Nieber; Norman J Oppenheimer; Sunna Hauschildt
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

10.  2'-Deoxyadenosine 5'-diphosphoribose is an endogenous TRPM2 superagonist.

Authors:  Ralf Fliegert; Andreas Bauche; Adriana-Michelle Wolf Pérez; Joanna M Watt; Monika D Rozewitz; Riekje Winzer; Mareike Janus; Feng Gu; Annette Rosche; Angelika Harneit; Marianne Flato; Christelle Moreau; Tanja Kirchberger; Valerie Wolters; Barry V L Potter; Andreas H Guse
Journal:  Nat Chem Biol       Date:  2017-06-26       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.